CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma

References

• Pro B, Dang N H. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004; 19: 1345–1351
   PubMed Web of Science ®Google Scholar
• Boonacker E, Van Noorden C J. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82: 53–73
   PubMed Web of Science ®Google Scholar
• Christopherson K W, Hangoc G, Broxmeyer H E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002; 169: 7000–7008
   PubMed Web of Science ®Google Scholar
• Christpherson K W, Cooper S, Broxmeyer H E. Cell surface peptidase CD26/DPPIV mediateds G-CSF mobilization of mouse progenitor cells. Blood 2003; 101: 4680–4686
   PubMed Web of Science ®Google Scholar
• Wesley U V, Albino A P, Tiwari S, Houghton A N. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999; 190: 311–322
   PubMed Web of Science ®Google Scholar
• Kikkawa F, Kajiyama H, Ino K, Shibata K, Mizutani S. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 2003; 105: 779–783
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003; 63: 2278–2283
   PubMed Web of Science ®Google Scholar
• Aytac U, Claret F X, Ho L, Sato K, Ohnuma K, Mills G B, et al. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 2001; 61: 7204–7210
   PubMed Web of Science ®Google Scholar
• Sato K, Aytac U, Yamochi T, Yamochi T, Ohnuma K, McKee K S, et al. CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. Br J Cancer 2003; 89: 1366–1374
   PubMed Web of Science ®Google Scholar
• Sato K, Dang N H. CD26: a novel treatment target for T-cell lymphoid malignancies?. Int J Oncol 2003; 22: 481–497
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, et al. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 1995; 86: 4617–4626
   PubMed Web of Science ®Google Scholar
• Ruiz P, Mailhot S, Delgado P, Amador A, Viciana A L, Ferrer L, Zacharievich N. CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma. Comm Clin Cytometry 1998; 34: 30–35
   PubMedGoogle Scholar
• Bauvois B, Meester I D, Dumont J, Rouillard D, Zhao H X, Bosmans E. Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer 1998; 79: 1042–1048
   Web of Science ®Google Scholar
• Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84: 3648–3652
   PubMed Web of Science ®Google Scholar
• Pulford K, Lamant L, Morris S W, Butler L H, Wood K M, Stroud D, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394–1404
   PubMed Web of Science ®Google Scholar
• Drexler H G, Gignac S M, von Wasielewski R, Werner M, Dirks W G. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000; 14: 1533–1559
   PubMed Web of Science ®Google Scholar
• Kameoka J, Tanaka T, Nojima Y, Schlossman S F, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466–469
   PubMed Web of Science ®Google Scholar
• Dong R P, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman S F, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997; 159: 6070–6076
   PubMed Web of Science ®Google Scholar
• Dong R P, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman S F, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156: 1349–1355
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Poletto D, Lorenzon D, Nanni P, Degan M, Olivo K, et al. CD26 expression correlates with a reduced sensitivity to 2′-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 1997; 15: 508–520
   Google Scholar
• Ichinohasama R, DeCoteau J F, Myers J, Kadin M E, Sawai T, Ooya K. Three-color flow cytometry in the diagnosis of malignant lymphoma based on the comparative cell morphology of lymphoma cells and reactive lymphocytes. Leukemia 1997; 11: 1891–1903
   PubMed Web of Science ®Google Scholar
• D'Haese J G, Tsukasaki K, Cremer F W, Fischer C, Bartram C R, Jauch A. Chromosomal aberrations in follicular non-Hodgkin lymphomas of Japanese patients, detected with comparative genomic hybridization and polymerase chain reaction analysis. Cancer Genet Cytogenet 2005; 162: 107–114
   PubMed Web of Science ®Google Scholar
• Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee K S, et al. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 2005; 65: 6950–6956
   PubMed Web of Science ®Google Scholar
• Kubonishi I, Sonobe H, Miyagi T, Iwahara Y, Ohyashiki J H, Ohyashiki K, et al. A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40, established from aggressive large cell lymphoma. Cancer Res 1990; 50: 7682–7685
   PubMed Web of Science ®Google Scholar
• Orscheschk K, Merz H, Hell J, Binder T, Bartels H, Feller A C. Large-cell anaplastic lymphoma-specific translocation (t[2;5][p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?. Lancet 1995; 345: 87–90
   PubMed Web of Science ®Google Scholar
• Yee H T, Ponzoni M, Merson A, Goldstein M, Scarpa A, Chilosi M, et al. Molecular characterization of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood 1996; 87: 1081–1088
   PubMed Web of Science ®Google Scholar
• Trumper L, Daus H, Merz H, von Bonin F, Loftin U, Cochlovius C, et al. NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: results from single-cell cDNA analysis. Ann Oncol 1997; 8: 83–87
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Audouin J, Ferme C, Briere J, Pulford K, Gaulard P, et al. ALK is not expressed in Hodgkin disease. Blood 2001; 97: 1901–1902
   PubMed Web of Science ®Google Scholar
• Herling M, Rassidakis G Z, Viviani S, Bonfante V, Giardini R, Gianni M, et al. Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: results with AL11 antibody in 327 untreated patients. Leuk Lymphoma 2001; 42: 969–979
   PubMed Web of Science ®Google Scholar
• Gorczyca W, Tsang P, Liu Z, Wu C D, Dong H Y, Goldstein M, et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Oncol 2003; 22: 319–324
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell 2004; 5: 353–364
   PubMed Web of Science ®Google Scholar